Targeting NF-κB signaling pathways presents a promising avenue for therapeutic therapies in smoking-associated lung cancer by interfering with critical processes that promote oncogenesis and progression (Bhat et al., 2024[22]; Wang et al., 2019[191]). This evidence concerns the gene NFKB1 and lung carcinoma.